Dr. Soliman Abdel Kader Fakeeh Hospital Full Year 2024 Earnings: Misses Expectations

Dr. Soliman Abdel Kader Fakeeh Hospital (TADAWUL:4017) Full Year 2024 Results

Key Financial Results

• Revenue: ر.س2.79b (up 20% from FY 2023).
• Net income: ر.س263.7m (down 5.7% from FY 2023).
• Profit margin: 9.4% (down from 12% in FY 2023). The decrease in margin was driven by higher expenses.
• EPS: ر.س1.32 (down from ر.س1.40 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Dr. Soliman Abdel Kader Fakeeh Hospital Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) also missed analyst estimates by 4.4%.

Looking ahead, revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Healthcare industry in Saudi Arabia.

Performance of the Saudi Healthcare industry.

The company's shares are down 2.0% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Dr. Soliman Abdel Kader Fakeeh Hospital's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.